한글목차

이 보고서는 세계 주요 바이오 제약사들이 체결한 유전자치료제 관련 계약에 대한 종합적인 이해와 전례 없는 정보 접근성을 제공합니다.

이 보고서에서는 기업이 유전자치료제 계약을 체결하는 과정과 이유에 대한 자세한 이해와 분석을 제공합니다. 이러한 계약은 공동 연구개발에서 시작하여 성과물의 상업화까지 여러 요소를 포함하는 경향이 있습니다.

이 보고서에는 공동연구, 개발, 연구, 라이선싱 계약이 포함되어 있습니다.

이 보고서에는 2016년 이후 발표된 787건의 유전자치료제 거래에 대한 종합적인 리스트이 포함되어 있으며, 거래 당사자가 공개한 실제 유전자치료제 제휴 거래의 온라인 기록에 대한 링크와 함께 재무 조건 및 거래 당사자가 공개한 거래 조건이 포함되어 있습니다. 또한 가능한 경우, 기업과 파트너가 증권거래위원회에 제출한 계약 문서도 기록에 포함됩니다.

주요 장점:

• 2016년 이후 계약 동향 파악
• 유전자치료 분야 공동연구 및 라이선스 계약 열람하기
• 벤치마크 분석 : 거래 시장 가치 파악
• 금융 조건: 계약금, 마일스톤 지급, 로열티, 계약금, 계약금
• 업체명(A-Z), 계약유형, 치료분야별 계약 디렉토리
• 금액 기준 주요 거래
• 가장 활발한 딜 제조업체
• 각 계약의 자산 내용 및 계약 조건 명시
• 계약 문서에 대한 액세스: 계약 구조에 대한 심층적인 인사이트
• 실사: 제안 중인 계약 조건이 파트너사에게 적합한지 여부를 평가
• 조사 시간 수백 시간 단축

계약 내용을 분석하면 다음과 같은 실사가 가능합니다.

• 계약에 의해 구체적으로 부여되거나 옵션으로 부여되는 권리의 내용은 무엇인가?
• 계약에 따라 제휴사에게 실제로 부여되는 권리는 무엇인가?
• 어떤 독점권이 부여되어 있는가?
• 계약금 지급 구조는?
• 매출과 결제는 어떻게 감사하는가?
• 계약 기간은?
• 계약의 주요 조항은 어떻게 정의되어 있는가?
• 지적재산권(IPR)은 어떻게 취급되며, 누가 소유하고 있는가?
• 상업화의 책임은 누가 져야 하는가?
• 개발, 공급, 제조는 누가 책임질 것인가?
• 기밀 유지 및 공개는 어떻게 관리되는가?
• 분쟁은 어떻게 해결되는가?
• 어떤 조건으로 계약을 해지할 수 있는가?
• 소유권이 변경되면 어떻게 되는가?
• 서브 라이선스 및 하도급에 관한 조항은 어떻게 합의되어 있는가?
• 회사 측에서 반드시 넣어야 하는 모범조항은 무엇인가?
• 계약 상대방이나 계약 유형에 따라 달라지는 모범규준은 무엇인가?
• 계약법상 회사가 준거법으로 요구하는 법역(관할권)은 어디인가?

목차

개요

제1장 서론

제2장 유전자 치료에 관한 계약 동향

• 과거 수년간 유전자 치료 계약 건수
• 가장 활발한 계약 체결 기업
• 유전자 치료 계약 : 계약 유형별
• 유전자 치료 계약 : 치료 분야별
• 유전자 치료 계약 : 산업 부문별
• 유전자 치료 계약의 거래조건

제3장 주요 유전자 치료 계약

• 주요 유전자 치료 계약 : 계약금액별

제4장 가장 활발한 유전자 치료 계약 체결 기업

• 가장 활발한 유전자 치료 계약 체결 기업
• 가장 활발한 유전자 치료 계약 체결 기업 개요

제5장 유전자 치료 계약 거래 디렉토리

• 유전자 치료 계약 거래 디렉토리

제6장 유전자 치료 계약 : 기술 유형별

• 계약 디렉토리
• 계약 디렉토리 기업별(A-Z)
• 계약 디렉토리 계약 유형별
• 계약 디렉토리 치료 분야별
• 계약 유형 정의
• Biopharma Research Ltd 소개
• Current Partnering
• Current Agreements
• Current Partnering으로부터의 최근 리포트 타이틀

영문목차

Gene Therapy Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the gene therapy deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of gene therapy deals from 2016 to 2025.

The report provides a detailed understanding and analysis of how and why companies enter gene therapy deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 787 gene therapy deals announced since 2016 including financial terms where available including links to online deal records of actual gene therapy partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of gene therapy dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in gene therapy dealmaking since 2016.

Chapter 3 provides an overview of the leading gene therapy deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in gene therapy dealmaking with a brief summary followed by a comprehensive listing of gene therapy deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of gene therapy deals signed and announced since Jan 2016, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of gene therapy partnering deals signed and announced since Jan 2016. The chapter is organized by specific gene therapy technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in gene therapy deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Gene Therapy Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse gene therapy collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Gene Therapy Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of gene therapy trends and structure of deals entered into by leading biopharma companies worldwide.

Gene Therapy Collaboration and Licensing Deals includes:

• Trends in gene therapy dealmaking in the biopharma industry
• Directory of gene therapy deal records covering pharmaceutical and biotechnology
• The leading gene therapy deals by value
• Most active gene therapy licensing dealmakers
• Gene Therapy Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in gene therapy dealmaking

• 2.1. Introduction
• 2.2. Gene therapy deals over the years
• 2.3. Most active gene therapy dealmakers
• 2.4. Gene therapy deals by deal type
• 2.5. Gene therapy deals by therapy area
• 2.6. Gene therapy deals by industry sector
• 2.7. Deal terms for gene therapy deals
  • 2.7.1 Gene therapy deals headline values
  • 2.7.2 Gene therapy deal upfront payments
  • 2.7.3 Gene therapy deal milestone payments
  • 2.7.4 Gene therapy royalty rates

Chapter 3 - Leading gene therapy deals

• 3.1. Introduction
• 3.2. Top gene therapy deals by value

Chapter 4 - Most active gene therapy dealmakers

• 4.1. Introduction
• 4.2. Most active gene therapy dealmakers
• 4.3. Most active gene therapy deals company profiles

Chapter 5 - Gene therapy contracts dealmaking directory

• 5.1. Introduction
• 5.2. Gene therapy contracts dealmaking directory

Chapter 6 - Gene therapy dealmaking by technology type

• Deal directory
• Deal directory - Gene therapy deals by company A-Z
• Deal directory - Gene therapy deals by deal type
• Deal directory - Gene therapy deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Gene therapy deals since 2016
• Figure 2: Active gene therapy dealmaking activity - 2016 - 2025
• Figure 3: Gene therapy deals by deal type since 2016
• Figure 4: Gene therapy deals by therapy area since 2016
• Figure 5: Gene therapy deals by industry sector since 2016
• Figure 6: Gene therapy deals with a headline value
• Figure 7: Gene therapy deals with an upfront value
• Figure 8: Gene therapy deals with a milestone value
• Figure 9: Gene therapy deals with a royalty rate value
• Figure 10: Top gene therapy deals by value since 2016
• Figure 11: Most active gene therapy dealmakers 2016 - 2025
• Figure 12: Gene therapy deals by technology type since 2016